MIR4317: A Drug Target / Disease Biomarker (G100422840)
MIR4317: A Drug Target / Disease Biomarker
MIR4317, also known as ITGA210, is a gene that has been shown to play a role in the development and progression of various diseases, including cancer. It has also been identified as a potential drug target and biomarker.
MIR4317 is a non-coding RNA molecule that is expressed in a variety of tissues and cells throughout the body. It is a member of the ITGA2 family, which is known for its role in cell-signaling and development. The ITGA2 family has been shown to play a role in the development and progression of various diseases, including cancer.
One of the most promising aspects of MIR4317 is its potential as a drug target. The ITGA2 family has been shown to be involved in the development of various types of cancer, including breast, ovarian, and prostate cancers. MIR4317 has been shown to be highly expressed in these types of cancer, and it has also been shown to interact with severalit drugs that are commonly used to treat these cancers.
In addition to its potential as a drug target, MIR4317 has also been identified as a potential biomarker. The ITGA2 family has been shown to be involved in the development and progression of various diseases, including cancer. MIR4317 has been shown to be highly expressed in these types of diseases, and it has also been shown to interact with several biomarkers that are commonly used to diagnose and treat these diseases.
One of the most promising aspects of MIR4317 is its potential to be used as a drug or biomarker for the treatment of various types of cancer. The ITGA2 family has been shown to play a role in the development and progression of these types of diseases, and MIR4317 has been shown to interact with several drugs that are commonly used to treat these cancers. Further research is needed to fully understand the potential of MIR4317 as a drug or biomarker for the treatment of cancer.
Protein Name: MicroRNA 4317
The "MIR4317 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4317 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR4318 | MIR4319 | MIR432 | MIR4320 | MIR4321 | MIR4322 | MIR4323 | MIR4324 | MIR4325 | MIR4326 | MIR4327 | MIR4328 | MIR4329 | MIR433 | MIR4330 | MIR4418 | MIR4420 | MIR4423 | MIR4425 | MIR4427 | MIR4428 | MIR4429 | MIR4430 | MIR4431 | MIR4432 | MIR4432HG | MIR4433A | MIR4433B | MIR4435-1 | MIR4435-2 | MIR4435-2HG | MIR4436A | MIR4436B1 | MIR4436B2 | MIR4437 | MIR4440 | MIR4441 | MIR4442 | MIR4443 | MIR4444-1 | MIR4444-2 | MIR4445 | MIR4446 | MIR4447 | MIR4448 | MIR4449 | MIR4450 | MIR4451 | MIR4453 | MIR4453HG | MIR4454 | MIR4455 | MIR4456 | MIR4457 | MIR4458 | MIR4458HG | MIR4463 | MIR4465 | MIR4466 | MIR4467 | MIR4468 | MIR4469 | MIR4470 | MIR4472-1 | MIR4472-2 | MIR4474 | MIR4475 | MIR4476 | MIR4478 | MIR4479 | MIR448 | MIR4481 | MIR4482 | MIR4483 | MIR4484 | MIR4485 | MIR4486 | MIR4487 | MIR4488 | MIR4489 | MIR4491 | MIR4492 | MIR4493 | MIR4496 | MIR4497 | MIR4498 | MIR4499 | MIR449A | MIR449B | MIR449C | MIR4500 | MIR4500HG | MIR4501 | MIR4504 | MIR4505 | MIR4506 | MIR4507 | MIR4508 | MIR4509-1 | MIR4509-2
